395 related articles for article (PubMed ID: 29984503)
21. Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.
DeFilippis EM; Givertz MM
Curr Heart Fail Rep; 2016 Jun; 13(3):111-8. PubMed ID: 27188181
[TBL] [Abstract][Full Text] [Related]
22. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
23. A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever.
Basile JN
Hosp Pract (1995); 2016; 44(1):9-20. PubMed ID: 26781810
[TBL] [Abstract][Full Text] [Related]
24. Adverse Effects Associated With Newer Diabetes Therapies.
Akiyode OF; Adesoye AA
J Pharm Pract; 2017 Apr; 30(2):238-244. PubMed ID: 26169212
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
[TBL] [Abstract][Full Text] [Related]
26. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
[TBL] [Abstract][Full Text] [Related]
27. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
28. The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.
Kim GS; Park JH; Won JC
Endocrinol Metab (Seoul); 2019 Jun; 34(2):106-116. PubMed ID: 31099200
[TBL] [Abstract][Full Text] [Related]
29. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
Tanaka A; Node K
Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
[TBL] [Abstract][Full Text] [Related]
30. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
Avogaro A; Delgado E; Lingvay I
Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
[TBL] [Abstract][Full Text] [Related]
31. Hot Topics in Primary Care: Considerations in the Selection of Antihyperglycemic Therapy for Older Patients With Type 2 Diabetes Mellitus: A Focus on Newer Therapies.
Freeman J
J Fam Pract; 2015 Dec; 64(12 Suppl):S59-66. PubMed ID: 26845016
[TBL] [Abstract][Full Text] [Related]
32. Network meta-analysis of cardiovascular outcomes in randomized controlled trials of new antidiabetic drugs.
Fei Y; Tsoi MF; Kumana CR; Cheung TT; Cheung BMY
Int J Cardiol; 2018 Mar; 254():291-296. PubMed ID: 29277321
[TBL] [Abstract][Full Text] [Related]
33. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce Cardiovascular Risk in Adults With Type 2 Diabetes Mellitus.
Sharma A; Verma S
Can J Diabetes; 2020 Feb; 44(1):93-102. PubMed ID: 31882322
[TBL] [Abstract][Full Text] [Related]
35. Glucose-Lowering Medications and Cardiovascular Outcomes.
Shanmugasundaram M; Pineda JRE; Murugapandian S
Curr Cardiol Rep; 2021 Mar; 23(4):24. PubMed ID: 33655453
[TBL] [Abstract][Full Text] [Related]
36. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.
Yandrapalli S; Jolly G; Horblitt A; Pemmasani G; Sanaani A; Aronow WS; Frishman WH
Cardiol Rev; 2020; 28(4):177-189. PubMed ID: 32282393
[TBL] [Abstract][Full Text] [Related]
37. Implications of Cardiovascular Outcomes Trials in Type 2 Diabetes for Primary Care.
Unger J
J Fam Pract; 2018 Jun; 67(6 suppl):S35-S40. PubMed ID: 29912999
[TBL] [Abstract][Full Text] [Related]
38. New Treatments for Type 2 Diabetes Mellitus and Cardiovascular Disease. The Revolution Has Begun.
Simó R; Hernández C
Rev Esp Cardiol (Engl Ed); 2016 Nov; 69(11):1005-1007. PubMed ID: 27659856
[No Abstract] [Full Text] [Related]
39. New Agents for the Treatment of Type 2 Diabetes.
Libianto R; Ekinci EI
Crit Care Clin; 2019 Apr; 35(2):315-328. PubMed ID: 30784612
[TBL] [Abstract][Full Text] [Related]
40. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes.
Nassif ME; Kosiborod M
Am J Cardiol; 2019 Dec; 124 Suppl 1():S12-S19. PubMed ID: 31741435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
